United Therapeutics Corp. (UTHR) announced Monday morning that it received a second complete response letter from the FDA, declining to approve its new drug application for treprostinil diolamine extended release tablets, for the treatment of pulmonary arterial hypertension.
United Therapeutics gapped open sharply lower Monday and is now down 3.44 at $57.51 on above average volume. The stock has dropped below a range at the highs of the year and has set a 1-month low.
For comments and feedback: editorial@rttnews.com